Sanofi (Sanofi) 3-Year EPS without NRI Growth Rate : 2.00% (As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi 3-Year EPS without NRI Growth Rate?

Sanofi's EPS without NRI for the six months ended in Jun. 2023 was $1.72.

During the past 12 months, Sanofi's average EPS without NRI Growth Rate was -20.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 2.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Sanofi was 37.90% per year. The lowest was -18.20% per year. And the median was 8.10% per year.

Competitive Comparison of Sanofi's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Sanofi's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sanofi's 3-Year EPS without NRI Growth Rate falls into.

Sanofi 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Sanofi (NAS:SNY) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Sanofi 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Sanofi's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.